Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Days Payable

: 55.97 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Catalyst Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2023 was $9.7 Mil. Catalyst Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $15.8 Mil. Hence, Catalyst Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 55.97.

The historical rank and industry rank for Catalyst Pharmaceuticals's Days Payable or its related term are showing as below:

CPRX' s Days Payable Range Over the Past 10 Years
Min: 35.78 Med: 65.92 Max: 89.68
Current: 43.8

During the past 13 years, Catalyst Pharmaceuticals's highest Days Payable was 89.68. The lowest was 35.78. And the median was 65.92.

CPRX's Days Payable is ranked worse than
76.61% of 714 companies
in the Biotechnology industry
Industry Median: 149.875 vs CPRX: 43.80

Catalyst Pharmaceuticals's Days Payable increased from Dec. 2022 (26.51) to Dec. 2023 (55.97). It may suggest that Catalyst Pharmaceuticals delayed paying its suppliers.

Catalyst Pharmaceuticals Days Payable Historical Data

The historical data trend for Catalyst Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

79.81

89.68

58.58

35.78

65.92

Catalyst Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															26.51	33.79	29.59	29.05	55.97

Competitive Comparison

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalyst Pharmaceuticals Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Days Payable falls into.

Catalyst Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Catalyst Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (3.975	+	14.795)	/	2 )	/	51.967	*	365
=	9.385					/	51.967	*	365
=	65.92

Catalyst Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (4.598	+	14.795)	/	2 )	/	15.809	*	365 / 4
=	9.6965					/	15.809	*	365 / 4
=	55.97

Catalyst Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CN2:Germany

Address

355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134

Website

https://www.catalystpharma.com

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Executives

Molly Harper	director	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande	officer: Chief Accounting Officer	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito	officer: Chief Medical Officer	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller	officer: VP Development & Management	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany	director, 10 percent owner, officer: President and Chief Executive	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del	officer: Chief Commercial Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd	officer: Chief Compliance/Legal Officer	355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe	director	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram	officer: Chief Product Devel. Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan	officer: Chief Commercial Officer	C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship	officer: V.P. of Regulatory Operations	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134